Biomarker for ovarian and endometrial cancer: hepcidin
AssigneesVermilllion, Inc., The John Hopkins University, Board of Regents, The University of Texas System
InventorsValdimir Podust, Zhen Zhang, Eric T. Fung, Robert Bast, Daniel W. Chan, Jin Song
Life of this patent
Estimating the term…
Abstract
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Claims14
A method for qualifying ovarian cancer status in a subject comprising:
- (a) measuring the level of hepcidin in a biological sample from the subject being screened for ovarian cancer;
- and (b) correlating the measurement of an increased level of hepcidin in the biological sample from the subject as compared to the level of hepcidin in a biological sample from a healthy subject with the diagnosis of ovarian cancer.
Dependencies are inferred from the claim text.